Nuvectis Pharma Shares Plunge 34% After $100M Stock Offering Prices at $20
NVCT has more than doubled off its 52-week low of $5.55 on elevated volume (9.6× avg).
Summary
Nuvectis Pharma shares plunged 34% to $18.91 after the company priced a public offering of 5 million common shares at $20.00 each, aiming to raise $100 million. This follows the company's announcement of the offering's commencement on June 29th and the pricing details earlier today. The $100 million capital raise is substantial, providing a significant cash runway given their Q1 net loss of $6.05 million and cash burn of $6.51 million. However, the market is reacting strongly negative to the dilution, with shares falling below the offering price, indicating investor concern about the terms or the need for such a large raise.
At the time of this announcement, NVCT was trading at $18.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $497.5M. The 52-week trading range was $5.55 to $29.28. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.